Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Manage your formulary budget
|Title:||Sustained release formulations of water soluble peptides|
|Abstract:||The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.|
|Inventor(s):||Bodmer; David (Klingnau, CH), Fong; Jones W. (Parsippany, NJ), Kissel; Thomas (Staufen, DE), Maulding, Jr.; Hawkins V. (Mendham, NJ), Nagele; Oskar (Sissach, CH), Pearson; Jane E. (Ogendensburg, NJ)|
|Assignee:||Sandoz Ltd. (Basel, CH)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.